A5028726302- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Acute Myeloid Leukemia Research
- T-cell and B-cell Immunology
- Cutaneous lymphoproliferative disorders research
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Nanoplatforms for cancer theranostics
- HIV/AIDS drug development and treatment
- Single-cell and spatial transcriptomics
- Microtubule and mitosis dynamics
- Cellular Mechanics and Interactions
- Prenatal Screening and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- Angiogenesis and VEGF in Cancer
- Protein Degradation and Inhibitors
- Caveolin-1 and cellular processes
Brigham and Women's Hospital
2022-2024
Harvard University
2024
Broad Institute
2023
Women's Hospital
2023
The University of Queensland
2015-2021
Mater Research
2015-2021
Translational Research Institute
2019-2020
Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute disease pathology in peripheral tissues
Cross-presentation is the mechanism by which exogenous Ag processed for recognition CD8(+) T cells. Murine CD8α(+) DCs are specialized at cross-presenting soluble and cellular Ag, but in humans this process poorly characterized. In study, we examined uptake cross-presentation of human blood CD141(+) DCs, equivalent mouse compared them with monocyte-derived (MoDCs) CD1c(+) DC subsets. MoDCs were superior their capacity to internalize cross-present protein whereas more efficient ingesting Ag....
Background The conventional type 1 dendritic cell subset (cDC1) is indispensable for tumor immune responses and the efficacy of checkpoint inhibitor (ICI) therapies in animal models but little known about role human CD141 + DC cDC1 equivalent patients with melanoma. Methods We developed a flow cytometry assay to quantify characterize blood subsets healthy donors stage 3 4 metastatic To examine whether harnessing DCs could improve ICIs melanoma, we humanized mouse model by engrafting...
Abstract New targeted therapies such as the selective and potent BCL-2 inhibitor Venetoclax have revolutionized treatment of acute myeloid leukemia (AML). However, due to cellular heterogeneity disease, drug-resistant cell types often emerge drive relapse. We found that eukaryotic translation initiation factor 4A (EIF4A) is highly expressed in multiple primitive AML compared their healthy counterparts, suggesting its potential a therapeutic target. By unwinding complex structures 5’ UTR...
Targeted therapies like Venetoclax have increased the options available to acute myeloid leukemia (AML) patients, but survival remains poor due drug resistance and disease relapse. We found that translation initiation factor EIF4A1, which unwinds complex mRNA structures in 5' UTR of oncogenic transcripts, is highly expressed AML stem- progenitor-like cells. Inhibiting eIF4A with small molecule Zotatifin reduces transcripts related cell cycle survival. This results downregulation AKT, STAT-5,...
Abstract Dendritic cells (DCs) as professional antigen-presenting with unique T-cell stimulatory capacity represent a potential means by which to improve response rates towards immune checkpoint inhibitor antibodies (ICIs) such anti-PD-1 (pembrolizumab) in melanoma. The conventional type 1 DC subset (cDC1) is indispensable for the efficacy of ICIs animal models; however, very little known about role cDC1 human cancer patients. To address this, we developed whole-blood assay quantifying and...